Navigation Links
Beckman Coulter's 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook
Date:2/8/2008

care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represent more than 78 percent of the company's 2007 revenue of $2.76 billion. For more information, visit http://www.beckmancoulter.com.

Forward Looking Statements

This press release contains the company's unaudited financial results for the fourth quarter of 2007. These results may change as a result of further review by the company's independent accountants and management. The completion of the audit of our financial statements could result in additional changes to our financial results and could result in the identification of issues relating to the effectiveness of our internal control over financial reporting. Final fourth quarter and annual results will be provided in the company's annual report to the SEC on Form 10-K.

This press release also contains forward-looking statements regarding the company's outlook for 2008, including expectations for revenue growth, operating margin, non-operating expense, pretax profit growth, tax rate, earnings per diluted share, capital expenditures, and depreciation and amortization. In addition, the press release contains statements about the company's expectations regarding effects on free cash flow and EBITDA resulting from the Company's move from sales-type leases to an operating-type lease business model, commercialization of its UniCel DxC 880i work cell and UniCel DxH hematology system, and the effects of new technologies and emerging markets on the Company's market growth.

These statements are based on information available at the time they are made and are subject to a number of risks and uncertainties. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, some of which may be beyond the company's control. Risk factors that affect the company are discu
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine news :

1. Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University
2. Beckman Coulter Signs Agreements With Amerinet, Inc.; Ten-Year Partnership Extended for Another Three Years
3. Beckman Coulter to Present at the Credit Suisse Global Healthcare Conference
4. Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako
5. Beckman Coulter to Present at the 2007 RBC Capital Markets Healthcare Conference
6. Haemacure Reports Third Quarter 2007 Results
7. Weight Watchers Declares Quarterly Dividend
8. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
9. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
10. Medical Services International Maintains Pace in Second Quarter
11. Martek Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...ine enough to disrupt normal development, mouse st... News) -- Just a few glasses of wine over a short ..., suggest researchers from the Medical College of ...syndrome, which affects one in 1,000 babies, inclu...per lip, small eye openings, and a short nose. Res...
(Date:8/29/2008)...ug. 29 /PRNewswire-FirstCall/ -- InterMune, Inc.,(...ch, Chairman, CEO and,President of InterMune, will...Conference in Boston on September 4, 2008 at 10:55... presentation, investors and other,interested part...nterMune,s,corporate website at http://www.interm...
(Date:8/29/2008)...ust 29 /PRNewswire/ --, - MYA Cosmetic Surgery Se...other Stars but the big Question is who Will be Ne...nd and being on national,television for an hour ea...bout the way you look. For many previous Big Broth...ving the house contestants may undoubtedly spend,h...
(Date:8/29/2008)... 10-year study published in the August 28 issue of...magnesium sulfate administered to women delivering...cerebral palsy by 50 percent. The Beneficial Effec... conducted in 18 centers in the U.S., including No...ervention ever found to reduce the instance of cer...
Breaking Medicine News(10 mins):Health News:Alcohol in Early Pregnancy May Prompt Fetal Cell Death 2Health News:MYA Makes Big Brother Stars Amazing! 2Health News:MYA Makes Big Brother Stars Amazing! 3Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2
...t and humidity that lead to dehydration can signal...research presented this week at the American// Col...Washington DC. Gout, caused by deposits of monoso... and swelling of the joints. The attacks, which ty...
...s for cardiac patients who still would love to hav...And doctors have news that will sweep you off// yo...atients who were assigned waltz classes randomly s...nal measures and quality of life than those cardia...
...s of young people giving them reason to attempt su...was led by Peter Watson at Auckland University and... Pediatrics and Child Health. It revealed that 34 ...ne problem had thought about killing themselves wh...
...so far, Ranchi registered its first death from the...ic relations officer of the Central Mines Planning...IL) undertaking, died of dengue Sunday night. He w...ak Hospital here Saturday. The doctors said he w...
Other Medicine News:Health News:It's the Heat and the Humidity: How Each Worsens Gout Symptoms 2
(Date:8/27/2008)...e VELCADE, melphalan and prednisone arm demonstrat...0 percent complete response -, CAMBRIDGE, Mass., ...ology Company today announced the publication of r... VISTA(1) trial in this week,s edition of the,New ...significant survival,benefit and a 30 percent comp...
(Date:8/26/2008)...g. 26 /- The Oregon Tourism Commissio...er Service Training Program,(Q Care) this week on ... training program created to support the tourism a...education. By emphasizing,the importance of qualit...ees with tools and resources to better serve Orego...
(Date:8/26/2008)...as, Aug. 26 /- Healthpoint today anno...aluate the effectiveness of a,widely prescribed en...s and,resulting scars. The pilot study was prompte...idence of hypertrophic scars and beneficial healin... Ointment.(1,2), "Given the findings from the pee...
(Date:8/25/2008)...em Cells Found in Menstrual Blood May Offer Long-L...Pressed Women, OLDSMAR, Fla., Aug. 25 /PRNewswire...men would agree that there never seems to be enoug...ds on doing something just,for herself usually pal....,This reality has led many women in need of quali...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Oregon Tourism Commission Unveils New Online Customer Service Training Program 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits 2Loving the Memory Impaired 3A A New Perspective on Valentines Day 11545 1Loving the Memory Impaired 3A A New Perspective on Valentines Day 11545 2Pennsylvania DEP Releases 4th Quarter 2007 Mammography Inspection Results 11541 1Pennsylvania DEP Releases 4th Quarter 2007 Mammography Inspection Results 11541 2Pennsylvania DEP Releases 4th Quarter 2007 Mammography Inspection Results 11541 3Pennsylvania DEP Releases 4th Quarter 2007 Mammography Inspection Results 11541 4Investor Insight Initiates Analyst Coverage on Crdentia 11538 1Investor Insight Initiates Analyst Coverage on Crdentia 11538 2Baxter Provides Update on Heparin Reactions 3186 1Baxter Provides Update on Heparin Reactions 3186 2Baxter Provides Update on Heparin Reactions 3186 3
...- New product recently approved by FDA for long-te...on; data demonstrate first,nebulized formoterol fu...to dry powder formoterol, enhanced patient quality...lif., May 20, 2007 /PRNewswire/ -- Data presented ...oracic Society (ATS),demonstrate that Perforomist ...
...ata Also Show Nebivolol Lowers Blood Pressure in O... May 21, 2007 /PRNewswire-FirstCall/ -- Forest,Lab... two clinical,studies and one pooled analysis of n...ting properties currently under review by,the U.S....ent of,hypertension. Data from the two clinical st...
Other Medicine Technology:Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 2Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 3Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 4
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 6.0 mm and length 10 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 11.0 mm and length 10 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 8 mm.
Medicine Products: